Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Dec 28, 2016
    TEL-AVIV, Israel, Dec. 28, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and canc...
    PDF
    Dec 27, 2016
    TEL-AVIV, Israel, Dec. 27, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and ...
    PDF
    Dec 21, 2016
    TEL-AVIV, Israel, Dec. 21, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and ...
    PDF
    Dec 20, 2016
    TEL-AVIV, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and ...
    PDF
    Dec 19, 2016
    The first patients have been screened and a first patient has been dosed in the open-label, dose escalation Phase Ib/II study with YELIVA® (ABC294640) for multiple myelomaThe Phase Ib/II clinical study is intended to evaluate the safety and efficacy of YELIVA® in up to 77 patients with refractory or relapsed multiple myeloma who have prev...
    PDF
    Dec 14, 2016
    RedHill and its co-development partner, IntelGenx Corp. (IntelGenx), have signed a definitive agreement with Pharmatronic Co., granting an exclusive license to commercialize the acute migraine drug RIZAPORT®¬†in South Korea This agreement follows the previously announced commercialization agreement with Grupo JUSTE S.A.Q.F for Spain, and the ...
    PDF
    Dec 13, 2016
    Following a pre-planned review of safety data, RedHill has received a unanimous recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the MAP US Phase III study with RHB-104 for Crohn's disease as planned, without any modificationsA second DSMB meeting, expected in Q2/2017, will include an interim efficacy analysis...
    PDF
    Dec 12, 2016
    Thought to be autoimmune in nature, the multiple sclerosis (MS) inflammatory process is also consistent with an infectious disease; The CEASE-MS Phase IIa proof-of-concept (PoC), single-arm, open-label study was designed with a series of exploratory endpoints to evaluate the safety and potential efficacy of fixed oral-dose RHB-104 as an add-on ther...
    PDF
    Dec 5, 2016
    TEL-AVIV, Israel, Dec. 05, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and canc...
    PDF
    Nov 21, 2016
    The poster, to be presented at the upcoming EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, describes results from non-clinical studies conducted by Apogee Biotechnology Corp. demonstrating the potential antitumor and anti-inflammatory effects of YELIVA™ (ABC294640) in combination with radiation YELIVA™ is a proprie...
    PDF
    Page: FirstPrevious
    3
    ... NextLast

    Subscribe to press releases